ZH United Lab (IFC-40467)

Countries
  • China
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Proposed
Bank Risk Rating
B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Borrower
THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED
The holder of the loan, grant, or other investment.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 90.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Loan Amount (USD)
$ 90.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Jan 30, 2019

Disclosed by Bank Nov 29, 2018


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

According to IFC website, the United Laboratories International Holdings Limited is a leading generic pharmaceutical producer in China. TUL manufactures antibiotics finished products, insulin products, and active pharmaceutical ingredients and it is one of the largest penicillin-based antibiotics producers in China. The Company plans to upgrade and expand its manufacturing facilities in China, invest in the marketing of insulin products and spend on long-term research and development.     

Investment Description
  • International Finance Corporation (IFC)
Private Actors

The United Laboratories International Holdings Limited manufactures insulin products, antibiotics, pharmaceutical intermediary products, and bulk medicine for domestic consumptions in China and for exports to overseas markets.

Contact Information

The United Laboratories International Holdings Limited
No contact information provided at the time of disclosure. 

ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/